

RESEARCH REPORT



ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKETS, STRATEGIES AND TRENDS BY PATHOGEN AND TECHNOLOGY, WITH EXECUTIVE GUIDES AND CUSTOMIZATION. 2022 TO 2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides.....	17
1.1	Antimicrobial Resistance - Strategic Situation Analysis	18
1.2	Guide for Executives and Business Development Staff.....	20
1.3	Guide for Management Consultants and Investment Advisors.....	22
2	Introduction and Market Definition	23
2.1	The Threat and Opportunity of Antimicrobial Resistance	24
2.2	Defining the Opportunity.....	27
2.2.1	Revenue Market Size	27
2.3	Methods and Sources.....	29
2.3.1	Methodology	29
2.3.2	Sources	29
2.3.3	Authors.....	30
2.4	U.S. Antibiotic Markets - Perspective.....	31
2.4.1	U.S. Outpatient Use of Antibiotics.....	32
2.4.2	U.S. Pharmaceutical Spending.....	35
3	Overview of a Dynamic Market	37
3.1	Market Players – Roles & Impacts.....	38
3.1.1	Drug manufacturers - Larger/pharmaceutical	39
3.1.2	Drug manufacturers - Generic	40

3.1.3	Contract Research and Manufacturing	41
3.1.4	In Vitro Diagnostics Industry	42
3.1.5	Drug Marketing Companies	43
3.1.6	Biotechnology Companies	43
3.1.7	Regulatory Bodies	44
3.2	Understanding Antimicrobial Resistance	46
3.2.1	What is Antimicrobial Resistance (AMR)	46
3.2.2	Bacteria and Other Microbes.....	47
3.2.3	The History of Antibiotics.....	54
3.2.4	The Role of Animal Husbandry.....	59
3.2.5	The Implications of Horizontal Transfer.....	60
3.2.6	The Threat of AMR	62
3.3	The Changing Road to New Antibiotics & Technologies.....	64
3.4	The Key Role of Diagnostics in AMR.....	67
4	The Market Opportunity of AMR	68
4.1	The Key Large Market Opportunities in AMR	69
4.1.1	Streptococcus Pneumoniae (DRSP)	70
4.1.2	Campylobacter (DRC)	73
4.1.3	Clostridium Difficile (CD)	76
4.1.4	Staphylococcus aureus (MRSA)	79
4.1.5	Neisseria gonorrhoeae (DRNG)	83
4.1.6	Salmonella (DRNTS)	87

4.2	Diagnostic Technology Development Opportunities.....	90
4.2.1	What's Wrong with Microbiology	92
4.2.2	The Features Battleground of Infectious Disease Diagnostics.....	92
4.2.3	Multiplex vs. POC/Rapid.....	92
4.2.4	The Miracle of Genetics	93
4.2.5	From Multiple Pathogens to All Pathogens – The Next Next Generation	95
4.2.6	Gene Sequence Diagnostics WITHOUT the Sequencing.....	95
4.2.7	Markers of Resistance.....	96
4.2.8	What Happens to the Microbiology Lab?	96
5	Antibiotic Resistance Diagnostics Recent Developments	97
5.1	Antibiotic Resistance Recent Developments	98
5.1.1	Importance of These Developments.....	98
5.1.2	How to Use This Section	98
5.2	T2 Biosystems Exercises BARDA Option	98
5.3	OpGen to Ramp up Use of Acuitas AMR Gene Panel.....	100
5.4	BD Partners With Pfizer, Wellcome to Study AMR Dx.....	104
5.5	Sepsis Test Developers Accelerate Plans	105
5.6	OpGen Receives FDA Clearance for AMR Panel.....	111
5.7	Visby Medical - Rapid Uptake of Handheld PCR Test for STIs.....	112
5.8	MicroGenDx, OrthoKey Clinic and OrthoKey Surgery.....	114
5.9	BioMérieux Receives CE Mark for Vitek Clinical Microbiology System.....	115

5.10	Hologic to Acquire Mobidiag	116
5.11	Campylobacter strains exchange genes	117
5.12	Disinfection spreads antimicrobial resistance	120
5.13	Molzym, Fraunhofer Developing Rapid Sepsis Dx	121
5.14	Illumina, IDbyDNA Build NGS-Based Respiratory Panel	127
5.15	Accelerate Diagnostics Expands AMR Testing	133
5.16	Rapid diagnostics linked to optimal antibiotics	134
5.17	Visby Medical Wins AMR Diagnostic Competition	135
5.18	DNAe Technology SARS-CoV-2 Sequences.....	136
5.19	Infections with foodborne bacteria becoming harder to treat...	138
5.20	Dust is sharing antibiotic resistance genes.....	141
5.21	Report predicts drug resistance likely to kill 400,000	142
5.22	New method to test for infection resistance.	146
5.23	Qiagen launches AMR database	148
5.24	Antibiotic resistance test for gonorrhea gets FDA breakthrough	150
5.25	Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics	151
6	Key AMR Diagnostics Companies	153
6.1	1928 Diagnostics	154
6.2	Abacus Diagnostica	155
6.3	Abbott Laboratories.....	156
6.4	Accelerate Diagnostics	158

6.5	ADT Biotech.....	159
6.6	Beckman Coulter Diagnostics	160
6.7	Becton, Dickinson and Company.....	161
6.8	Binx Health.....	163
6.9	bioMérieux Diagnostics.....	165
6.10	Bio-Rad Laboratories, Inc.	168
6.11	Cepheid (Danaher)	171
6.12	Curetis N.V. / Curetis GmbH.....	173
6.13	Day Zero Diagnostics.	175
6.14	Enzo Biochem.....	176
6.15	Eurofins Scientific	178
6.16	Fusion Genomics.	181
6.17	GeneFluidics.....	183
6.18	Genetic Signatures.....	184
6.19	Great Basin Corporation	186
6.20	Hologic.....	188
6.21	Hutman Diagnostics	191
6.22	Inflammatix.....	192
6.23	Linear Diagnostics.....	194
6.24	Lumos Diagnostics	195
6.25	Millipore Sigma.....	196
6.26	OpGen.....	197

6.27	Ortho Clinical Diagnostics	199
6.28	Perkin Elmer	201
6.29	Qiagen.....	203
6.30	Roche Molecular Diagnostics.....	206
6.31	SeLux Diagnostics	208
6.32	Sense Biodetection	210
6.33	Siemens Healthineers	212
6.34	Sysmex.....	215
6.35	Thermo Fisher Scientific Inc.	218
6.36	Visby Medical.....	221
7	The Global Market for Antimicrobial Resistance Diagnostics	223
7.1	Global Market Overview by Country.....	224
7.1.1	Table – Global Market by Country.....	224
7.1.2	Chart - Global Market by Country	225
7.2	Global Market by Technology - Overview.....	226
7.2.1	Table – Global Market by Pathogen	226
7.2.2	Chart – Global Market by Pathogen – Base/End Year Comparison.....	227
7.2.3	Chart – Global Market by Pathogen – Base Year.....	228
7.2.4	Chart – Global Market by Pathogen – End Year	229
7.2.5	Chart – Global Market by Pathogen – Share by Year	230
7.2.6	Chart – Global Market by Pathogen – Segment Growth	231

7.3	Global Market by Technology - Overview.....	232
7.3.1	Table – Global Market by Technology	232
7.3.2	Chart – Global Market by Technology – Base/End Year Comparison.....	233
7.3.3	Chart – Global Market by Technology – Base Year	234
7.3.4	Chart – Global Market by Technology – End Year	235
7.3.5	Chart – Global Market by Technology – Share by Year	236
7.3.6	Chart – Global Market by Technology – Segment Growth.....	237
8	Global Antibiotic Resistance Diagnostic Markets – By Pathogen	238
8.1	Drug Resistant Streptococcus Pneumoniae - DRSP	239
8.1.1	Table DRSP – by Country	239
8.1.2	Chart - DRSP Growth.....	240
8.2	Drug Resistant Campylobacter - DRC	241
8.2.1	Table DRC – by Country	241
8.2.2	Chart - DRC Growth.....	242
8.3	Clostridium Difficile - CD	243
8.3.1	Table CD – by Country	243
8.3.2	Chart - CD Growth	244
8.4	Methicillin Resistant Staphylococcus Aureus - MRSA.....	245
8.4.1	Table MRSA – by Country	245
8.4.2	Chart – MRSA Growth	246
8.5	Drug Resistant Neisseria Gonorrhoeae - DRNG.....	247

8.5.1	Table DRNG – by Country	247
8.5.2	Chart – DRNG Growth	248
8.6	Drug Resistant Salmonella - DRNTS	249
8.6.1	Table DRNTS – by Country	249
8.6.2	Chart – DRNTS Growth	250
9	Global Antibiotic Resistance Diagnostic Markets – by Technology	251
9.1	Microbiology Culture	252
9.1.1	Table Culture – by Country	252
9.1.2	Chart – Culture Growth	253
9.2	Immunoassay	254
9.2.1	Table Immunoassay – by Country	254
9.2.2	Chart - Immunoassay Growth	255
9.3	PCR	256
9.3.1	Table PCR – by Country	256
9.3.2	Chart - PCR Growth	257
9.4	NGS	258
9.4.1	Table NGS – by Country	258
9.4.2	Chart - NGS Growth	259
9.5	Mass Spectrometry - MS	260
9.5.1	Table MS – by Country	260
9.5.2	Chart - MS Growth	261
9.6	Rapid and Point of Care – Rapid/POC	262

9.6.1 Table Rapid/POC – by Country262

9.6.2 Chart - Rapid/POC Growth263

10 Vision of the Future of AMR Diagnostics264

11 Appendices.....265

11.1 United States Medicare System: 2022 Clinical Laboratory Fees Schedule.....265

Table of Tables

Table 1 USA - Outpatient Use of Antibiotics by Class	33
Table 2 USA - Outpatient Use of Antibiotics Top 5	34
Table 3 Market Players by Type.....	38
Table 4 Known Human Pathogenic Diseases.....	50
Table 5 The Key Market Opportunities	69
Table 6 - Market Potential DRSP Diagnostic	72
Table 7 - Market Potential DRC Diagnostic	75
Table 8 - Market Potential CD Diagnostic	77
Table 9 - Market Potential CD Diagnostic	81
Table 10 Market Potential DRNG Diagnostic.....	85
Table 11 Market Potential DRNTS Diagnostic	88
Table 12 – Key AMR Diagnostics Issues.....	90
Table 13 - Global Market by Region.....	224
Table 14 Global Market by Pathogen.....	226
Table 15 Global Market by Technology.....	232
Table 16 DRSP by Country.....	239
Table 17 DRC by Country.....	241
Table 18 CD by Country	243

Table 19 MRSA by Country245

Table 20 DRNG by Country.....247

Table 21 DRNTS by Country.....249

Table 22 Culture by Country.....252

Table 23 Immunoassay by Country254

Table 24 PCR by Country256

Table 25 NGS by Country258

Table 26 MS by Country260

Table 27 Rapid/POC by Country262

Table 28 2022 Clinical Lab Fee Schedule265

Table of Figures

Figure 1 Pharmaceutical Spending History by Country	35
Figure 2 AMR and Antibiotic Introduction	58
Figure 3 The Death Toll of AMR.....	62
Figure 4 Global Market Share Chart.....	225
Figure 5 Global Market by Pathogen – Base vs. End Year	227
Figure 6 Global Market by Pathogen Base Year	228
Figure 7 Global Market by Pathogen End Year.....	229
Figure 8 Pathogen Share by Year.....	230
Figure 9 Pathogen Segment Growth	231
Figure 10 Technology - Base vs. End Year Segment Shift.....	233
Figure 11 Technology Market Base Year.....	234
Figure 12 Technology Market End Year	235
Figure 13 Technology Share by Year.....	236
Figure 14 Technology Segment Growth	237
Figure 15 DRSP Growth	240
Figure 16 DRC Diagnostics Growth.....	242
Figure 17 CD Growth	244
Figure 18 MRSA Growth.....	246
Figure 19 DRNG Growth	248

Figure 20 DRNTS Growth 250

Figure 21 Culture Growth 253

Figure 22 Immunoassay Growth..... 255

Figure 23 PCR Growth..... 257

Figure 24 NGS Growth 259

Figure 25 MS Growth..... 261

Figure 26 Rapid/POC Growth..... 263